描述
Sofosbuvir is a nucleotide analog prodrug that targets the HCV NS5B RNA-dependent RNA polymerase, critical to viral replication . As the active ingredient in the brand Sovaldi, it is a key compound in antiviral research. Dongyangguang’s formulation offers the same active molecule with local approval for research purposes. Use cases include in vitro replication assays, resistance models, combination therapy studies, and hepatocyte metabolism research.
Sofosbuvir Tablets Product Specifications
Parameter | Details |
---|---|
Product Name | Sofosbuvir Tablets (Dongyangguang) |
Generic Name | Sofosbuvir |
CAS Number | 1190307?88?0 |
Molecular Formula | C??H??FN?O?P |
Molecular Weight | ~529.45?g/mol |
Strength | 400?mg per tablet |
Pack Size | 0.4?g × 28 tablets |
Dosage Form | Film-coated oral tablet |
Approval Number | H20233865 (NMPA China) |
Manufacturer | Yichang Dongyangguang Changjiang Pharma Co., Ltd. |
Barcode | 6933346881016 |
Storage Conditions | Store ??30?°C in a cool, dry place |
Intended Use | Laboratory research—HCV virology, NS5B inhibitor studies, antiviral screening |
Sofosbuvir Tablets Mechanism of Action
Sofosbuvir is metabolized into a triphosphate form in hepatocytes, which then competitively inhibits the HCV NS5B polymerase, terminating viral RNA synthesis, and offering a high barrier to resistance
Sofosbuvir Tablets Research Applications
-
HCV replication assays targeting NS5B
-
Antiviral resistance modeling against direct-acting antivirals
-
Combination treatment studies (e.g., with NS5A or protease inhibitors)
-
Pharmacokinetic and metabolic activation studies in hepatic cells
-
Structure–activity relationship research in viral polymerase inhibition
Safety & Handling
-
Use under research-grade lab conditions only
-
Standard PPE required: gloves, lab coat, eye protection
-
Synthesized to pharmaceutical standards but not for clinical administration
-
Store in original packaging, protected from heat and moisture
Core Keywords
sofosbuvir tablets, Dongyangguang Sofosbuvir, CAS 1190307-88-0, HCV NS5B inhibitor, hepatitis C antiviral compound, preclinical HCV drug, antiviral research sofosbuvir, NMPA H20233865, Yichang Dongyangguang
Research Use Disclaimer
This product is exclusively for laboratory and research use. It is not approved for clinical, veterinary, diagnostic, or therapeutic use. Misuse may result in legal or health implications. Use only under institutional protocol.
评价
目前还没有评价